Performance of pro-adrenomedullin for identifying adverse outcomes in community-acquired pneumonia

Journal of Infection

Volumn 70, Issue 5, 2015, Pages 457-466

  España, Pedro P ^a   Capelastegui, Alberto ^a   Mar, Carmen ^a   Bilbao, Amaia ^b   Quintana, José M ^a   Diez, Rosa ^a   Esteban, Cristobal ^a   Bereciartua, Edurne ^a   Unanue, Unai ^a   Uranga, Ane ^a  

^a HOSPITAL DE GALDAKAO   (Spain)

^b HOSPITAL DE BASURTO   (Spain)

Author keywords

Biomarkers; C reactive protein; Community acquired pneumonia; Pro adrenomedulin; Procalcitonin

Indexed keywords

C REACTIVE PROTEIN; PROADRENOMEDULLIN; PROCALCITONIN; ADRENOMEDULLIN; BIOLOGICAL MARKER; CALCITONIN; PROTEIN PRECURSOR;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; CURB 65 SCORE; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PLEURA EFFUSION; PNEUMONIA SEVERITY INDEX; PROGNOSIS; PROGNOSTIC ASSESSMENT; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RESPIRATORY FAILURE; RISK ASSESSMENT; SCAP SCORE; SHOCK; AGED; AMBULATORY CARE; AREA UNDER THE CURVE; BLOOD; COMMUNITY-ACQUIRED INFECTIONS; COMPLICATION; EMERGENCY HEALTH SERVICE; HOSPITALIZATION; ISOLATION AND PURIFICATION; MIDDLE AGED; PNEUMONIA; PREDICTIVE VALUE; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

ADRENOMEDULLIN; ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE; AREA UNDER CURVE; BIOMARKERS; C-REACTIVE PROTEIN; CALCITONIN; COMMUNITY-ACQUIRED INFECTIONS; EMERGENCY SERVICE, HOSPITAL; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PNEUMONIA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; ROC CURVE; SEVERITY OF ILLNESS INDEX;

EID: 84926688497     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2014.12.003     Document Type: Article

References (39)

1. Lim W.S., Woodhead M. British Thoracic Society adult community acquired pneumonia audit 2009/10. Thorax 2011 Jun, 66(6):548-549. On behalf of the British Thoracic Society.
2. Welte T., Torres A., Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 2012 Jan, 67(1):71-79.
3. Fine M.J., Auble T.E., Yealy D.M., Hanusa B.H., Weissfeld L.A., Singer D.E., et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997, 336:243-250.
4. Lim W.S., van der Eerden M.M., Laing R., Boersma W.G., Karalus N., Town G.I., et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003 May 56, 296-301.
5. España P.P., Capelastegui A., Gorordo I., Esteban C., Oribe M., Ortega M., et al. Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am J Respir Crit Care Med Dec 1 2006, 174:1249-1256.
6. España P.P., Capelastegui A., Quintana J.M., Bilbao A., Diez R., Pascual S., et al. Validation and comparison of SCAP as a predictive score for identifying low-risk patients in community-acquired pneumonia. J Infect 2010 Feb, 60(2):106-113. [Epub 2009 Dec 2].
7. Carratalà J., Fernández-Sabé N., Ortega L., Castellsagué X., Rosón B., Dorca J., et al. Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients. Ann Intern Med 2005, 142:165-172.
8. Labarere J., Stone R.A., Obrosky S., Yealy D.M., Meehan T.P., Fine J.M., et al. Comparison of outcomes for low-risk outpatients and inpatients with pneumonia. A propensity-adjusted analysis. Chest 2007 Feb, 131(2):480-488.
9. Ewig S., Woodhead M., Torres A. Towards a sensible comprehension of severe community-acquired pneumonia. Intensive Care Med 2011 Feb, 37(2):214-223. [Epub 2010 Nov 16].
10. Pereira J.M., Paiva J.A., Rello J. Severe sepsis in community-acquired pneumonia - early recognition and treatment. Eur J Intern Med 2012, 23(5):412-419.
11. Brown J.S. Biomarkers and community-acquired pneumonia. Thorax 2009, 64:556-558.
12. Christ-Crain M., Opal S.M. Clinical review: the role of biomarkers in the diagnosis and management of community-acquired pneumonia. Crit Care 2010, 14:203.
13. Flanders S.A., Stein J., Shochat G., Sellers K., Holland M., Maselli J., et al. Performance of a beside C-reactive protein test in the diagnosis of community-acquired pneumonia in adults with acute cough. Am J Med 2004, 116(8):529-535.
14. Simon L., Gauvin F., Amre D.K., Saint-Louis P., Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004, 39(2):206-217.
15. Gilbert D.N. Use of plasma procalcitonin levels as an adjunt to clinical microbiology. J Clin Microbiol 2010, 48:2325-2329.
16. Gilbert D.N. Procalcitonin as a biomarker in respiratory tract Infection. Clin Infect Dis 2011 May, 52(Suppl. 4):S346-S350.
17. Masia M., Gutierrez F., Shum C., Padilla S., Navarro J.C., Flores E., et al. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity Index. Chest 2005 Oct, 128(4):2223-2229.
18. Prat C., Dominguez J., Andreo F., Blanco S., Pallarés A., Cuchillo F., et al. Procalcitonin and neopterin correlation with aetiology and severity of pneumonia. J Infect 2006 Mar, 52(3):169-177.
19. Schuetz P., Batschwaroff M., Dusemund F., Albrich W., Bürgi U., Maurer M., et al. Division of Internal Medicine, University Hospital Basel. Effectiveness of a procalcitonin algorithm to guide antibiotic therapy in respiratory tract infections outside of study conditions: a post-study survey. Eur J Clin Microbiol Infect Dis 2010 Mar, 29(3):269-277.
20. Krüger S., Ewig S., Marre R., Richter K., von Baum H., Suttorp N., et al. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J 2008, 31(2):349-355.
21. Menendez R., Martinez R., Reyes S., Mensa J., Filella X., Marcos M.A., et al. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax 2009 Jul, 64(7):587-591.
22. Alfageme I., Aspa J., Bello S., Blanquer J., Blanquer R., Borderías L., et al. Guidelines for diagnosis and management of community-acquired pneumonia. Spanish Society of Pulmonology and Thoracic Surgery (SEPAR). Arch Bronconeumol 2005, 41(5):272-289.
23. Caruhel P., Mazier C., Kunde J., Morgenthaler N., Darbouret B. Homogeneous time-resolved fluoroimmunoassay for the measurement of midregional proadrenomedullin in plasma on the fully automated system B.R.A.H.M.S KRYPTOR. Clin Biochem 2009, 42:725-728.
24. España P.P., Capelastegui A., Quintana J., Diez R., Gorordo I., Bilbao A., et al. Prospective comparison of severity scores for predicting clinically relevant outcomes for patients hospitalized with community-acquired pneumonia. Chest 2009 Jun, 135(6):1572-1579. [Epub 2009 Jan 13].
25. Hanley J.A., McNeil B.J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982, 143:29-36.
26. Hanley J.A., McNeil B.J. A method of comparing areas under receiver operating characteristic curves derived from the same cases. Radiology 1983, 148:839-843.
27. Albrich W.C., Dusemund F., Rüegger K., Christ-Crain M., Zimmerli W., Bregenzer T., et al. Enhancement of CURB65 score with proadrenomedullin (CURB65-A) for outcome prediction in lower respiratory tract infections: derivation of a clinical algorithm. BMC Infect Dis 2011 May 3, 11:112.
28. Zhang H., Singer B. Recursive partitioning in the health sciences 1999, Springer-Verlag New York, Inc.
29. Hastie T., Tibshirani R., Friedman J. The elements of statistical learning. Data mining, inference and prediction 2009, 29. Springer, New York.
30. Steyerberg E.W. Clinical prediction models 2009, Springer-Verlag, New York.
31. Blasi F., Stolz D., Piffer F. Biomarkers in lower respiratory tract infections. Pulm Pharmacol Ther 2010, 23(6):501-507.
32. Huang D.T., Weissfeld L.A., Kellum J.A., Yealy D.M., Kong L., Martino M., et al. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann Emerg Med 2008 Jul, 52(1):48-58.
33. Christ-Crain M., Morgenthaler N.G., Stolz D., Müller C., Bingisser R., Harbarth S., et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397]. Crit Care 2006, 10(3):R96. [Epub 2006 Jun 28].
34. Huang D.T., Angus D.C., Kellum J.A., Pugh N.A., Weissfeld L.A., Struck J., et al. Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia. Chest 2009 Sep, 136(3):823-831.
35. Krüger S., Ewig S., Giersdorf S., Hartmann O., Suttorp N., Welte T. Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: results from the German Competence Network, CAPNETZ. Am J Respir Crit Care Med 2010 Dec 1, 182(11):1426-1434. German Competence Network for the Study of Community Acquired Pneumonia (CAPNETZ) Study Group, [Epub 2010 Jul 16].
36. Schuetz P., Wolbers M., Christ-Crain M., Thomann R., Falconnier C., Widmer I., et al. Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections. Crit Care 2010, 14(3):R106. ProHOSP Study Group, [Epub 2010 Jun 8].
37. Bello S., Lasierra A.B., Mincholé E., Fandos S., Ruiz M.A., Vera E., et al. Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology. Eur Respir J 2012 May, 39(5):1144-1155. [Epub 2011 Nov 10].
38. Khan S.Q., O'Brien R.J., Struck J., Quinn P., Morgenthaler N., Squire I., et al. Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. J Am Coll Cardiol 2007 Apr 10, 49(14):1525-1532. [Epub 2007 Mar 26].
39. Dieplinger B., Mueller T., Kollerits B., Struck J., Ritz E., von Eckardstein A., et al. Pro-A-type natriuretic peptide and pro-adrenomedullin predict progression of chronic kidney disease: the MMKD Study. Kidney Int 2009 Feb, 75(4):408-414.